Rhein biotech NV

What Rhein biotech NV does

Rhein biotech NV is a privately held for-profit biotechnology company, as indicated by its self-classified short description and private IPO status. The firm maintains a web presence at rheinbiotech.com, but no further operational detail is disclosed in the provided source material.

The input data contains no product, pipeline, technology, customer, headcount, revenue model, pricing, partnership, regulatory, or geographic information specific to Rhein biotech NV. All firmographic arrays (headcount, office locations, customer segments, distribution channels, products and services, patents, awards, leadership, investments, M&A, and regulatory actions) are empty. No source-attributed facts about commercial activity, scale, scientific focus, or strategic positioning are present.

A separate, unrelated data block covers Dynavax Technologies Corporation, a public commercial-stage vaccine company, and is included in the input stream only as adjacent context. No source material in this dataset establishes a corporate, technological, or commercial linkage between Rhein biotech NV and Dynavax, and the two should not be conflated. On the available evidence, Rhein biotech NV's current operational status, scientific focus, and commercial posture cannot be characterized beyond its self-identified status as a private biotechnology company.

Name

Rhein biotech NV

Legal name

Dynavax Technologies Corporation

Website

https://rheinbiotech.com

Company type

Public

Operating status

Operating

Short description

Rhein biotech NV is a privately held for-profit biotechnology company with a corporate web presence at rheinbiotech.com. No products, customers, technologies, or operating signals are documented in the available source material.

Ownership category

akta.pro rank

Product category

Biotechnology

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAG

Infectious Disease & Antimicrobials Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Biotechnology research
• Biopharmaceutical development
• Life sciences products
• Biotech manufacturing
• Biological products

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

Rhein biotech NV is categorized as a biotechnology company in the firmographic record. The input does not describe specific products, services, or commercial offerings for Rhein biotech NV; the detailed biopharmaceutical content present in the source aggregation pertains to Dynavax Technologies Corporation rather than Rhein biotech NV.

Differentiator

Problem solved

Functional benefit

Brands

• HEPLISAV-B: Marketed adult hepatitis B vaccine
• CpG 1018

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Expansion highlights1 record

Direct peers

• Novavax: Commercial-stage vaccine developer with proprietary adjuvant technology (Matrix-M) and a marketed recombinant protein vaccine, offering a directly comparable platform-vaccine business model to Rhein biotech NV.
• Emergent BioSolutions: Specialty vaccine and biologics developer with CDMO capabilities across infectious disease programs, comparable to Rhein biotech NV in the niche vaccine/biologics manufacturing space.
• Dynavax Technologies: Direct peer and apparent affiliated entity: commercial-stage biopharma built around the CpG 1018 TLR adjuvant platform and the HEPLISAV-B hepatitis B vaccine, sharing the same vaccine/biologics orientation that defines Rhein biotech NV.
• Bavarian Nordic: European-headquartered vaccine specialist focused on infectious disease (smallpox/mpox, HPV, RSV), directly comparable in scale, geography, and biologics-platform orientation to Rhein biotech NV.

Broad incumbents

• GSK: Global vaccines major with established adjuvant systems (AS01, AS03) and a broad infectious-disease portfolio, representing the broader incumbent competitive set Rhein biotech NV's platform competes within.
• Sanofi: Global pharmaceutical major with a significant vaccines franchise (Sanofi Pasteur) and the acquirer of Dynavax; highly relevant incumbent peer given its direct ownership of the CpG 1018 platform via the December 2025 deal.
• Moderna: Commercial-stage biotech with a broad mRNA vaccine and adjuvant-delivery platform spanning infectious disease (COVID-19, RSV, flu), serving as a broad incumbent in the same vaccine/adjuvant space.

Others

• Lonza Group: Global biopharmaceutical contract development and manufacturing organisation with extensive biologics/vaccine manufacturing capabilities, comparable as the type of bioprocessing/CDMO infrastructure that underpins Rhein biotech NV's business.
• Catalent: Major biopharma CDMO providing biologics manufacturing, fill-finish and gene therapy services, comparable as an adjacent infrastructure enabler for biologics and vaccine manufacturing similar to Rhein biotech NV's positioning.

Emerging players

• BioNTech: European-headquartered mRNA vaccine and immuno-therapy developer expanding into infectious-disease adjuvanted vaccines; comparable as an emerging biotech in the vaccine-adjacent space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

• Xtwitter.com/DynavaxCorp
• LinkedInlinkedin.com/company/dynavax-technologies

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rhein biotech NV